Literature DB >> 28132238

P008. Alexithymia and chronic migraine with medication overuse: what relationship?

Sara Bottiroli1, Federica Galli2, Michele Viana3, Grazia Sances3, Marta Allena3, Natascia Ghiotto3, Elena Guaschino3, Giorgio Sandrini3,4,5, Cristina Tassorelli3,4,5, Giuseppe Nappi3,5.   

Abstract

Entities:  

Year:  2015        PMID: 28132238      PMCID: PMC4715080          DOI: 10.1186/1129-2377-16-S1-A150

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


× No keyword cloud information.

Background

Alexithymia is a personality trait characterized by the inability to identify and express emotions. Neuroimaging studies showed specific neural correlates in alexithymic subjects [1] and pathological scores of alexithymia in several chronic pain populations and in episodic migraine [2, 3]. There is also evidence of a positive association between alexithymia, depression, and anxiety in migraine patients. So far, no study has evaluated alexithymia in medication-overuse headache patients (MOH) (progressed by migraine) versus episodic migraine patients (MIG). The present study was aimed to evaluate whether MOH individuals differ from MIG as regards alexithymia scores and to investigate the association of alexithymia with headache characteristics.

Materials and methods

We recruited 99 patients suffering from MOH (n=54; 81.5% female; age: 41.6±10.9) evolved from migraine (chronic migraine + MOH) or MIG (n=45; 71.6% female; age: 41.0±9.3) at the Headache Centre of the “Mondino” Institute of Pavia. Diagnosis in the 2 groups was operationally defined according to the ICHD-IIIβ criteria. Patients were evaluated using the Toronto Alexithymia Scale (TAS-20), which uses a five-point Likert response scale and has a three-factor structure consisting of: (1) Difficulty in identifying feelings, (2) Difficulty in describing feeling, and (3) Externally oriented thinking. Demographic and clinical information were collected as well.

Results

According to multiple binary logistic regression analysis, MIG and MOH patients were comparable in terms of demographic characteristics, whereas they differed for some characteristics of illness (age of migraine onset, duration of illness, frequency of headache), disability and QoL, as well as for depression levels. MOH patients scored higher than MIG on two of the three alexithymia facets, which were those concerning difficulties in identifying (MOH = 19.1±6.7, MIG = 13.8±6.7, p < 0.001) and describing feelings (MOH = 14.4±4.5, MIG = 11.6±4.8, p = 0.003). Groups were instead comparable in terms of externally oriented thinking (MOH = 18.6±4.2, MIG = 18.0±4.1, p = 0.50). Significant correlations resulted between alexithymia and illness characteristics (e.g., headache frequency, perceived disability, and QoL).

Conclusions

Our results show a specific alexithymic profile in our MOH population. These findings suggest that alexithymia could represent a risk factor in the transformation from episodic migraine into the chronic subtype with medication overuse. Early and appropriate interventions aimed at improving emotional awareness and expression could then represent a further preventive measure to avoid drug-induced headache. Written informed consent to publish was obtained from the patient(s).

Conflicts of interests

None.
  3 in total

1.  Individual differences in socioaffective skills influence the neural bases of fear processing: the case of alexithymia.

Authors:  Lydia Pouga; Sylvie Berthoz; Beatrice de Gelder; Julie Grèzes
Journal:  Hum Brain Mapp       Date:  2010-10       Impact factor: 5.038

2.  Alexithymia and its impact on quality of life in a group of Brazilian women with migraine without aura.

Authors:  Rebeca Veras de Andrade Vieira; Daniel Chaves Vieira; William Barbosa Gomes; Gustavo Gauer
Journal:  J Headache Pain       Date:  2013-02-25       Impact factor: 7.277

3.  Alexithymia is associated with greater risk of chronic pain and negative affect and with lower life satisfaction in a general population: the Hisayama Study.

Authors:  Mao Shibata; Toshiharu Ninomiya; Mark P Jensen; Kozo Anno; Koji Yonemoto; Seiko Makino; Rie Iwaki; Koji Yamashiro; Toshiyuki Yoshida; Yuko Imada; Chiharu Kubo; Yutaka Kiyohara; Nobuyuki Sudo; Masako Hosoi
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.